discontinue OCS Annual £99.45 per acquisition EXALT () patient costs of OCS Costs due to Manufacturer adverse £205.60 submission effects of () OCS Health losses due to Manufacturer 0.02331 adverse submission DALYs effects of () OCS 95%CI 95% confidence interval. – CSS clinical significant severe exacerbation; CSNS clinical significant non-severe – – exacerbation. Table S4 Model inputs for 3 exacerbations subgroup ≥ Adults and adolescents Children (patients 12 years) (patients 6-11 years) ≥ Variables Value Source Value Source Baseline annual rate of exacerbations INNOVATE≥3 IA-05 EUP ≥3 CSNS 2.2143 2.7651 exacerbations exacerbations exacerbations (1.8070 to 2.7133) (2.1763 to 3.5132) () ()
discontinue OCS Annual acquisition costs of OCS £99.45 per patient EXALT () Costs due to adverse effects of OCS £205.60 Manufacturer submission () Health losses due to adverse effects of OCS 0.02331 DALYs Manufacturer submission () 95%CI – 95% confidence interval. CSS – clinical significant severe exacerbation; CSNS – clinical significant non-severe exacerbation. Table S4 Model inputs for ≥ 3 exacerbations subgroup Adults and adolescents (patients ≥ 12 years) Children (patients 6-11 years) Variables Value Source Value Source Baseline annual rate of exacerbations CSNS exacerbations 2.2143 (1.8070 to 2.7133) INNOVATE≥3 exacerbations () 2.7651 (2.1763 to 3.5132) IA-05 EUP ≥3 exacerbations ()
1-s2.0-S1098301514019330-mmc1.docx